KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to -$27.1 million.

  • Twist Bioscience's Net Income towards Common Stockholders rose 21.79% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$77.7 million, marking a year-over-year increase of 62.79%. This contributed to the annual value of -$77.7 million for FY2025, which is 62.80% up from last year.
  • Latest data reveals that Twist Bioscience reported Net Income towards Common Stockholders of -$27.1 million as of Q3 2025, which was down 232.97% from $20.4 million recorded in Q2 2025.
  • Twist Bioscience's Net Income towards Common Stockholders' 5-year high stood at $20.4 million during Q2 2025, with a 5-year trough of -$85.6 million in Q2 2024.
  • In the last 3 years, Twist Bioscience's Net Income towards Common Stockholders had a median value of -$43.0 million in 2023 and averaged -$40.8 million.
  • As far as peak fluctuations go, Twist Bioscience's Net Income towards Common Stockholders plummeted by 69.47% in 2021, and later spiked by 123.82% in 2025.
  • Quarterly analysis of 5 years shows Twist Bioscience's Net Income towards Common Stockholders stood at -$45.6 million in 2021, then grew by 8.21% to -$41.8 million in 2022, then decreased by 2.83% to -$43.0 million in 2023, then rose by 26.53% to -$31.6 million in 2024, then rose by 21.79% to -$27.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$27.1 million for Q3 2025, versus $20.4 million for Q2 2025 and -$39.4 million for Q1 2025.